Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $337.45M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.41M
Average 1.73M
LRMR Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Larimar Therapeutics, Inc.NASDAQ: LRMR
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 85.18M shares rose 33.2% year over year, ahead of the +22.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +41.5% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +33.2% holds above the trailing-twelve-month pace of +22.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 72.95M USD
- Year-over-year change
- +19.1%
- 4-year CAGR
- +43.6%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 72.95M | +19.1% |
| FY2024 | 2024-12-31 | 61.26M | +39.5% |
| FY2023 | 2023-12-31 | 43.9M | +70.4% |
| FY2022 | 2022-12-31 | 25.76M | +50.1% |
| FY2021 | 2021-12-31 | 17.16M | — |
Weighted Avg Shares (Diluted) vs competitors
How LRMR compares with its peers on the latest reported figures
- LRMR's LTM Mar 2026 weighted avg shares (diluted) of 78.18M shares is the 5th highest of the 11 companies compared; the peer median is 62.69M shares.
- Its year-over-year change of +22.5% is the 4th highest of 11, against a peer median of +11.3%.
- Over three fiscal years its annual growth of +41.5% compares with a peer median of +21.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 161.69M | +14.3% | +41.6% | |
| LTM Mar 2026 | 99.9M | -0.5% | +6.4% | |
| LTM Mar 2026 | 98.99M | +37.1% | +23.4% | |
| LTM Mar 2026 | 88.66M | -7.8% | +3.7% | |
| LTM Mar 2026 | 78.18M | +22.5% | +41.5% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | 65.52M | +98.2% | +28.7% |
ENGNenGene Holdings Inc. | LTM Apr 2026 | 59.85M | +25.2% | +47.9% |
| LTM Mar 2026 | 48.56M | +12.5% | +19.7% | |
| LTM Mar 2026 | 29.75M | +10.2% | +4.1% | |
| LTM Mar 2026 | 20.78M | +1.0% | +1.1% | |
| LTM Mar 2026 | 9.94M | +8.7% | +232.7% | |
| Peer median (excluding LRMR) | 62.69M | +11.3% | +21.5% | |
Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.4M | 24.25M | 27.67M | 73.28M | 154.22M |
| Selling, General & Admin | 12.07M | 12.28M | 14.09M | 17.61M | 18.27M |
| Operating Expenses | 50.47M | 36.53M | 41.76M | 90.89M | 172.5M |
| Depreciation & Amortization | 326K | 318K | 311K | 318K | 350K |
| EBITDA | (50.31M) | (35.04M) | (36.64M) | (80.29M) | (165.32M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.47M) | (36.53M) | (41.76M) | (90.89M) | (172.5M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (171K) | 1.17M | 4.81M | 10.29M | 6.82M |
| Income Before Tax | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| EPS (Diluted) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| Weighted Avg Shares | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
| Weighted Avg Shares (Diluted) | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$3.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.